This document is one component of the PPTA donor history questionnaire documents. The PPTA donor history questionnaire documents must be used collectively.

PPTA Abbreviated Donor History Questionnaire (DHQ)
Directions for Use

Table of Contents

Purpose
Introduction
Methods of Administration
Full-Length PPTA DHQ Administration Frequency
PPTA Abbreviated DHQ
Optional Questions
Donor Acknowledgment Statement
Additional Questions
Capture Questions
PPTA aDHQ Directions for Use Flow Chart Format
Donor Deferrals
Documentation
Maintenance/Change Control
Glossary
References
Flow Charts
PPTA Abbreviated Donor History Questionnaire
Directions for Use

Purpose: The Plasma Protein Therapeutics Association (PPTA) Abbreviated Donor History Questionnaire (aDHQ) Directions for Use is a guideline designed as an aid for the plasma sourcing organizations to use in the development of specific company policies and training materials related to donor eligibility. The PPTA aDHQ Directions for Use does not replace the company policy for determining donor eligibility. Each source plasma collection organization must have a standard operating procedure (SOP) related to donor suitability to be used in conjunction with the Directions for Use. The Directions for Use does not replace an SOP for determining donor eligibility. Both the Directions for Use and the SOP must be available to staff performing health histories. Alternately, the Directions for Use contents may be transcribed into the SOP.

Introduction: The following documents are included in this package: a Full-Length PPTA DHQ and corresponding Directions for Use, the PPTA aDHQ with acknowledgment statement, and corresponding Directions for Use, a Risk Poster, and a Medication List. The PPTA DHQ must be administered on the day of donation and before collection. The plasmapheresis center staff must provide to the prospective donor the Risk Poster and the Medication List, and any other material that the plasmapheresis center’s company policy requires to be used with the PPTA DHQ. These documents should be incorporated into the company’s donor eligibility process, which includes the physical examination and informed consent (each having its own educational information), in a manner that conveys the importance of the donor history questions in protecting the donor’s health and the safety of the plasma supply and the responsibility of the donor to provide accurate information.

Methods of Administration: The method of administration of the PPTA DHQ should be in accordance with the plasmapheresis center’s company policy.

The questionnaires were designed to be used by a health historian in direct donor questioning or by self-administration, with follow-up review (if necessary) by a trained donor historian. A trained historian should be available to the prospective donor to answer any questions concerning eligibility or the donation process. Donor screening is an active process involving open communication between donors and trained donor historians. Donors should be encouraged to voice questions and concerns at any time during the screening and donation process. Company policies should require that donors be asked if they have questions and if they have had their questions answered. This does not need to be a specific question on the questionnaire, but may be incorporated into the donor eligibility process, including the physical examination, and/or put into the informed consent.

Self-administration may occur in a computer-assisted self interview (CASI) process. With CASI administration, the Risk Poster and Medication List can be provided in hard-copy form or in an electronic format. Formatting can be adjusted as long as the order and content are unchanged. For example, when using in an electronic format, the
posters and medication list may be presented in blocks of applicable information rather than presented in a single screen. Questions directed at one sex can be omitted from sex-specific questionnaire. Also, if the process requires an answer to each question before advancing to the next question, an optional choice of “not sure” may be added. As stated above, a trained historian should be available to a prospective donor to answer any questions concerning eligibility or the donation process and to clarify each “not sure” response. For further instructions, refer to the CASI manufacturer’s instructions and operator’s manual.

If the questionnaire is administered by a health historian in direct donor questioning, the heading before each section should be stated along with the question to ensure the specific timeframe or instruction is clear.

Deferral decisions can be made any time during the administration of the questionnaire. Individual company policies will dictate whether an eligibility decision can be made prior to completing the entire questionnaire. However, it is recommended that the questionnaire be completed before making a determination of eligibility since some deferrals are temporary, but others are indefinite/permanent. Depending on the sequence of questions, a donor could be deferred temporarily, only to return at a later date and discover that he/she is permanently deferred due to the answer to another question that was not answered on the previous visit.

**Full-Length PPTA DHQ Administration Frequency:** The Full-Length (FL)PPTA DHQ will be administered during the donor's initial visit (Applicant 1 donation) and second visit if that visit occurs within six months of the initial visit (Applicant 2 donation). A donor must complete the FL PPTA DHQ during their first and second visits. The two visits must be completed within a six-month period. For donors who continue to donate at least once every six months as a Qualified Donor, the FL PPTA DHQ will be administered annually during their physical examination. The FL PPTA DHQ also is administered any time that the donor does not meet the criteria for the use of the PPTA aDHQ as explained below.

**PPTA Abbreviated DHQ (aDHQ):** The PPTA aDHQ was designed to elicit important information from the frequent plasma donor. A plasma donor is eligible to use the PPTA aDHQ version beginning on their third (3rd) visit and if the donor continues to donate at least once every six months and remains a Qualified Donor. The FL PPTA DHQ must be administered at the annual physical examination and whenever the donor reverts to Applicant status. The administration of the PPTA DHQ tools are linked to the Applicant/Qualified Donor voluntary standard for tracking purposes only. Administration of the FL PPTA DHQ at Applicant 1 and 2 donations fulfills the DHQ portion of the “two separate medical screenings” but use of the aDHQ on the 3rd visit is not dependent on the receipt of results of “testing for HIV, HBV and HCV.”

**Optional Questions:** The PPTA aDHQ may be used to elicit information required by regulatory authorities outside of the US. Optional questions have been added to the aDHQ for this purpose. If used, they should be numbered consecutively.
**Donor Acknowledgment Statement:** The donor acknowledgment statement is added to the PPTA DHQ. At the completion of the questionnaire, donors must be asked to review the statement, agree not to donate if the donation could result in a potential risk to recipients and provide a signature or other documented acknowledgment. The use of the donor acknowledgment statement must be described in an SOP submitted to FDA/CBER in a BLA supplement.

**Additional Questions:** Plasma sourcing organizations may choose to add “local” additional questions to the end of the PPTA aDHQ. If a collection facility chooses to add “local” questions they should be grouped at the end of the aDHQ in the area designated for additional questions. Facilities should also use this area to incorporate new questions that are necessary due to new policies recommended by FDA and/or PPTA. This area should be used until such questions can be formally incorporated into the DHQ materials by PPTA. The questions will remain in the additional question section until a revised strategy for incorporation is found acceptable by FDA. If the new question(s) results from FDA guidance, incorporation and implementation of the new question(s) should be consistent with the current thinking in the FDA Guidance document that discussed the new question(s) or deferral.

**Capture Questions:** The PPTA aDHQ uses “capture questions” that may require donor historian intervention or follow up. Capture questions are general questions that when answered “yes” require additional questions or information to determine donor eligibility. Some follow-up questions are included in the PPTA aDHQ Directions for Use but since specific donor eligibility criteria may vary from one plasma sourcing organization to another, an affirmative response to some questions may require consultation with the plasmapheresis center’s company policy.

**PPTA aDHQ Directions for Use Flow Chart Format:** The PPTA DHQ Directions for Use is modular and uses flow-charting to guide organizations through the DHQ process. Each question is a complete section that begins on a new page so that changes to the PPTA DHQ and the PPTA aDHQ can be easily modified in the PPTA DHQ Directions for Use. If a sourcing organization uses one or any of the optional questions, the respective flow chart module should be numbered to match the question. Each section contains the following information:

- **Question:** Question number and the question.
- **Donor Eligibility:** This section provides additional information to the donor historian on donor eligibility with respect to each question.
- **Note:** Optional field that provides additional relevant information relating to the donor question.
- **Flow Chart:** Each question is flow-charted using standard flow-charting symbols.
- **Square:** Statement
Diamond: Question/decision point

Oval: Action

Arrow: Move to the next question

Each question ends with an arrow that indicates to “move to the next question;” however, plasmapheresis centers must follow their established policies to determine if the donor eligibility process is completed when it is known that the donor will be deferred.

**Donor Deferrals:** For some questions, a “yes” answer calls for a required donor deferral either indefinitely or for a specified period of time. A required deferral is designated in the flow chart by the Action “Defer donor” followed by “indefinitely” or with the time period established by FDA regulations/recommendations or “per company policy.” For the latter, the organizations will use their established policies and procedures to determine if and when the donor may be eligible to return. In some cases, such as a donor providing a history of having had cancer, company policy will dictate the follow-up questions that are required to determine donor eligibility. Evaluation “per company policy” may deem the donor eligible to donate without a period of deferral. Additionally, when a question provides information to support deferral of the donor “per company policy.” Per company policy cannot be less restrictive than what is clearly delineated in FDA policy.

**Documentation:** Answers to the questions that are cause for donor deferral must be documented according to the plasmapheresis center’s company policy. Each plasmapheresis center’s company policy must define how the donor responses to the follow up questions will be documented.

**Maintenance/Change Control:** PPTA is responsible for the maintenance of the PPTA DHQ project documents. Documents are posted on the PPTA website (www.pptaglobal.org). Periodically the PPTA DHQ, the accompanying documents or the directions for use will be updated or revised by the PPTA DHQ Task Force as required for compliance with regulatory and accrediting agencies. PPTA member companies will be notified of the changes and timeline for implementation in existing publications and on the PPTA website, and all updated documents will be made available on the website. It is the responsibility of plasmapheresis centers to make changes in their forms, procedures, and processes to incorporate these revisions within the specified time.
GLOSSARY

The following terms are defined in the context of their use in the PPTA DHQ

DONOR CLASSIFICATION

Applicant Donor – All individuals presenting themselves who have not been previously qualified as a donor within the past six (6) months.

Qualified Donor – All individuals who have been qualified for continued donations by successfully passing two donor medical history screenings and required viral testing.

QUESTIONNAIRE TERMS

Capture Question – A question that covers a broad topic. When an affirmative answer is given, additional follow-up questions to elicit additional information are asked by the donor historian. EXAMPLE: In the past eight weeks, have you donated whole blood, platelets, or plasma at another center?

Self-administered Questionnaire – A questionnaire that the donor completes on their own, followed by donor health historian review.

CASI – Computer-assisted Self-interviewing system. Most often the system consists of an interactive computer screen. Questions are asked in written format, with or without graphics and audio.

TYPES OF CONTACT

Contact with Blood – (1) a needlestick or other sharps injury from an instrument that has been used on any individual or patient; (2) exposure to non-intact skin (e.g., skin that is chapped, abraded, or afflicted with dermatitis); (3) a human bite that breaks the skin; (4) exposure to eye, nose, or mouth i.e., the mucous membranes.

Sexual Contact – The meaning of the words “sexual contact with” and “sex” are identical, and apply to any of the following activities, whether or not a condom or other protection was used: (1) Vaginal sex (contact between penis and vagina); (2) Oral sex (mouth or tongue on someone’s vagina, penis, or anus); (3) Anal sex (contact between penis and anus).

New Sexual Partner or Contact – The meaning of the words “new sexual partner” and “new sexual contact” are identical and are defined as: (1) having sex with someone for the first time or (2) having had sex with someone in a relationship that ended in the past and having sex again with that person in the last three months.
**Close Contact with Smallpox Vaccination Site** – Touching the vaccination site, including the bandages covering the vaccination site; touching/handling materials that might have come into contact with an unbandaged vaccination site including clothing, towels, and bedding.

**Lived With** – Residing in the same dwelling in which kitchen and bathroom facilities are shared. Donors that have the same address would not be considered under the term “lived with” unless kitchen and bathroom facilities are shared.

**TYPES OF DEFERRAL**

**Indefinite Deferral** – Prospective donor is unable to donate Source Plasma for someone else for an unspecified period of time due to current regulatory requirements.

**Permanent Deferral** – Prospective donor will never be eligible to donate Source Plasma for someone else.

**Temporary Deferral** – Prospective donor is unable to donate Source Plasma for a limited period of time.
References

Donor qualification requirements are located in Title 21, Code of Federal Regulations, [21 CFR 630 and 640] and in PPTA voluntary standards in its International Quality Plasma Program (IQPP). The requirements for the alternative and optional questions are based on international country requirements.

Additional donor qualification requirements may be found in FDA memoranda and guidance:

Acitretin (Soriatane) Safety Information: 
http://www.drugs.com/pro/soriatane.html

Aubagio (teriflunomide) Safety Information: 
https://www.aubagio.com/ms-therapy?s_mcid=ps-google-AO-branded-aubagio- efficacy#isi

CellCept (mycophenolate mofetil) Prescribing Information: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050722s021,050723s019, 050758s019,050759s024lbl.pdf

Dutasteride (Avodart) Safety Information: 

Erivedge (vismodegib) Safety Information: 

Valproate Safety Information: 
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018081s046_18082s031lbl.pdf

FDA Memorandum, December 4, 1995: Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis


FDA Guidance, October 2001: Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax

FDA Guidance, December 2002: Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients

FDA Guidance, August 2006: Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies

FDA Guidance, June 20, 2007: Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs

FDA Guidance, December 2010: "Lookback" for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV. (This document supersedes the guidance document of the same title, dated August 2007.)

FDA Guidance, June 2011: Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide

FDA Guidance, November 2011: Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection

FDA Guidance, October 2012: Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus

FDA Guidance, January 2017: Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus

FDA Guidance, September 2017: Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday

FDA Guidance, December 2017: Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry. (This document supersedes the guidance of the same title, dated 5/2010.)

FDA Guidance, October 2019: Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus

FDA Guidance, December 2020: Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis

FDA Guidance, May 2022: Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components
**Question #1:** Are you feeling healthy and well today?

**Donor Eligibility:** A donor should be free of infectious diseases on the day of donation. Donors who are not in good health should not donate until it is determined that the underlying condition is not cause for deferral. [21 CFR 630.10(a), (c) and (e)]

- **Q1:** Are you feeling healthy and well today?
  - Yes: Donor eligible
  - No: Consult company policy and assess donor to determine if deferral is indicated.

- **Is donor deferral indicated?**
  - No: Next question
  - Yes: Defer Donor per company policy
**Question #2:** Since you last donated plasma, have you taken any medications on the medication list in the time frames indicated?

**Donor Eligibility:** Donors taking certain designated medications in specific time frames must not donate plasma, whole blood, or platelets. Certain medications have been identified as having the potential to compromise the safety of the patient. [21 CFR 630.10(e)(2)(ii)], [21 CFR 630.10(e)(2)(ii), 21 CFR640.21(b)], FDA’s May 2023 HIV Guidance, Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products, III.B.2, 3, 4, FDA’s December 2007 Guidance, Collection of Platelets by Automated Methods, III.A, page 5

**Note:** Deferral for receiving human growth hormone was removed from the medication list with revision 2.1. However, deferral is required in the EU. If following EU requirements, “Growth hormone from human pituitary glands” must be added to the medication list with the indication “delayed growth in children,” deferral period “ever,” and reason for deferral “harm patients who received medications prepared from your plasma by increasing the risk of transmitting CJD or vCJD.”

![Diagram](image-url)
Question #3: Since you last donated plasma, have you been pregnant or are you pregnant now?

Donor Eligibility: A person with a known pregnancy or who has been pregnant in the last six weeks (six months if following European requirements) should not donate blood or plasma. [21 CFR 630.10(e)(2)(v)]
**Question #4:** Since you last donated plasma, have you had any new medical problems or diagnoses?

**Donor Eligibility:** Donors reporting new medical problems\(^1\) or diagnoses must be evaluated to determine if the underlying medical condition is cause for deferral. Consult company policy.

---

\(^1\) Medical Problems include any medical condition the donor considers reportable. Examples may be nausea, headaches, muscle, or skeletal pains.
**Question #5**: Since you last donated plasma, have you had any new medical treatments, vaccinations, or medications?

**Donor Eligibility:**
- Donors reporting new medical treatments\(^2\) must be evaluated to determine if the underlying medical condition is cause for deferral. Consult company policy.
- Certain vaccinations may contain a live virus. A donor who has been exposed to a live virus via vaccination should not serve as a plasma donor for at least four weeks after the vaccination. For other vaccinations, consult company policy.

---

\(^2\) Treatments may include physical therapy, chiropractic, or other regimen or therapy in a health care environment.
**Question # 6:** Since you last donated plasma, have you had contact with someone who had a smallpox vaccination?

**Donor Eligibility:** Certain vaccinations may contain a live virus. A donor who has been exposed to a live virus via vaccination should not serve as a donor. For other shots, consult company policy to determine eligibility. [FDA’s December 2002 Smallpox Guidance]

**Note:** JYNNEOS is administered as an attenuated, live, non-replicating virus preparation. There is no risk for spread to other parts of the body or other people. Therefore, no deferral is required for a donor that has been in contact with an individual that has received the JYNNEOS vaccine.

[Flow chart continues on next page]
Severe complications include the following: rash (resembling blisters) covering a small or large area of the body; necrosis (tissue death) in the area of exposure; encephalitis (inflammation of the brain); infection of the cornea (eye) and localized or systemic skin reaction in someone with eczema or other chronic skin condition.

---

*Severe complications include the following: rash (resembling blisters) covering a small or large area of the body; necrosis (tissue death) in the area of exposure; encephalitis (inflammation of the brain); infection of the cornea (eye) and localized or systemic skin reaction in someone with eczema or other chronic skin condition.
**Question #7:** Since you last donated plasma, have you donated whole blood, platelets, or plasma at another center?

**Donor Eligibility:** A donor who has donated a unit of whole blood should not donate blood or plasma for a period of eight weeks. A donor who has donated a double unit of red blood cells by apheresis should not donate blood or plasma for a period of 16 weeks. A donor who has donated platelets or plasma by apheresis should not donate more than two times in a seven-day period at intervals of no less than two days apart. For other blood components or conditions of collection (e.g., less than a unit of whole blood), the donor should be deferred for the period established in the company policy.
**Question #8:** Did you review the Risk Poster?

**Donor Eligibility:** The Risk Poster includes information on risk activities for HIV/AIDS, viral hepatitis, and other infectious diseases that may be transmitted through blood. Therefore, potential plasma donors must read Risk Poster information provided during the donor interview to determine if they are at risk of transmitting infectious diseases. [21 CFR 630.10(b), (c) and (g)(2)(ii)(A) and FDA’s 2023 HIV Guidance, III.A.1 and 2]

**Note:** The Risk Poster includes deferral periods recommended by FDA in May 2023. If companies include additional risk activities to address international requirements (e.g., MSM) or use more restrictive deferral periods than are recommended by FDA, the Risk Poster must be updated to reflect company policies. The deferral time periods should be displayed in the appropriate chronological order from “Ever” to “Currently have.”
Question #9: Do you have any questions about anything mentioned on the Risk Poster?

Donor Eligibility: The Risk Poster includes information on risk activities for HIV/AIDS, viral hepatitis, and other infectious diseases that may be transmitted through blood. Therefore, any change in risk activities reported by the donor must be evaluated to determine donor eligibility. For donor deferral follow company policy.
**Question #10:** Since you last donated plasma, does anything on the Risk Poster apply to you in the time frames indicated?

**Donor Eligibility:** The Risk Poster includes information on risk activities for HIV, viral hepatitis, and other infectious diseases that may be transmitted through blood. Therefore, any change in risk activities reported by the donor must be evaluated to determine donor eligibility. For donor deferral follow company policy.
**Question #11**: Since you last donated plasma, have you had a tattoo applied or had one touched-up?

**Donor Eligibility**: Persons who have received a tattoo in the previous 3 months are deferred for 3 months (or 4 months if following EU requirements) from the date of the tattoo application because there may be a risk of transmission of infectious diseases. If tattoos have been applied using sterile needles and non-reused ink (such as in establishments licensed by a state or credentialed by a responsible certifying body), donors may be acceptable for donation (follow company policy). While FDA does not require donors be deferred if tattoos were applied using sterile methods, as described above, if you follow European requirements you must defer donors for a minimum of 4 months (with NAT testing). [21 CFR 630.10(e)(1)(vi) and FDA’s 2023 HIV Guidance, III.B.14]
**Question #12:** Since you last donated plasma, have you had an ear or body piercing?

**Donor Eligibility:** Persons who have had ear or body piercing during the previous 3 months are usually deferred for 3 months (or 4 months if following EU requirements) from the date of procedure. Unless ear or body piercing has been done using single-use equipment, there may be a risk of transmission of infectious diseases. While FDA does not require donors be deferred if piercing was performed using sterile methods, as described above, if you follow European requirements, you must defer donors for a minimum of 4 months (with NAT testing).
Optional Question A: Since you last donated plasma, have you had surgery or a diagnostic, medical, or dental procedure?

Donor eligibility: Outside of the US, some regulators have interpreted the European Commission Directive 2004/33/EC, Annex III to require that donors having certain surgical, diagnostic, medical or dental procedures be deferred for a period of time. Reasons for deferral vary from concerns for donor health to risks to the blood or blood components collected from the donors. Endoscopic examination using flexible tubing is specifically noted to require a 4 month deferral when NAT testing is performed.
**Optional Question B:** Since you last donated plasma, have you had acupuncture?

**Donor Eligibility:** European Commission Directive 2004/33/EC, Annex III, requires deferral of donors who have received acupuncture unless performed by a qualified practitioner and with sterile single-use needles.